Panavance Therapeutics
Our Science
Pipeline
About Misetionamide
MOA
About
About Panavance
Leadership
Board of Directors
Advisors & Collaborators
Contact Panavance
Resources
Publications
Brochures
Videos
Press Releases
Events
Participate
Let’s engage
.
Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma- in vitro and in vivo.
July 13, 2017
/
0 Minute Read